There has been considerable uncertainty over what the Trump administration might do regarding states that have legalized marijuana despite federal laws against use of the drug. Those uncertainties intensified with President Trump's pick of Jeff Sessions as U.S. Attorney General. Sessions has been a longtime vocal opponent to marijuana legalization.
Continue Reading Below
Now, however, those concerns have been greatly alleviated. A bipartisan budget bill to avoid a government shutdown includes $1 trillion in spending, but not even a penny of that amount was allocated for Sessions to target states that have flouted federal anti-marijuana laws. Is this good news for marijuana stocks?
Image source: Getty Images.
Stating the states
It wasn't just that the budget bill omitted money for the attorney general to enforce federal laws in states that have legalized marijuana. If that were the case, Sessions could potentially divert some Department of Justice (DOJ) funds to go after those states.
The bill instead explicitly prohibits the DOJ from using budget money for this purpose. Here's the exact language in Section 537 of the bill:
There are a couple of things to note with the language of the bill. First, it specifically names 44 states plus the District of Columbia, Guam, and Puerto Rico. Twenty-nine of these states, along with the District of Columbia, Guam, and Puerto Rico, have enacted comprehensive medical-marijuana laws. The other 15 states listed have laws allowing limited access to medical marijuana. Even if he wanted to, Sessions won't be able to attempt to enforce federal laws in any of these states or territories.
Second, a couple of states that have passed medical-marijuana laws weren't included (perhaps because of an oversight by the congressional staff drafting the language of the amendment). North Dakota passed a comprehensive medical-marijuana law in November, while Indiana Gov. Eric Holcomb signed a bill on April 27 legalizing cannabidiol (CBD) for treating epilepsy.
Impact on marijuana stocks
You'd think this spending bill would be great for marijuana stocks. However, most marijuana stocks haven't moved much on the news of the bipartisan budget compromise. Why?
Some marijuana stocks simply aren't affected by the bill. Biotechs such asAxim Biotechnologies (NASDAQOTH: AXIM) must abide by U.S. Food and Drug Administration (FDA) regulations anyway. Others, such asAphria, target the Canadian market and aren't affected by U.S. laws.
But what about stocks of U.S.-based marijuana growers? One reason these stocks haven't taken off is that the letter of the law only applies to prohibiting use of funds to keep states from implementing medical marijuana laws.
Eight states plus the District of Columbia have enacted laws allowing recreational use of marijuana. Technically, the DOJ could go after these states. However, the budget bill does not specifically allocate funds for this purpose. This limitation, though, is significant because of the large markets in the states that have legalized recreational marijuana.
Perhaps the bigger issue is that the spending bill is only temporary. The bill only funds federal spending through September.
Why it's still important
Although the budget legislation hasn't served as a catalyst for marijuana stocks, it's still important in the big scheme of things. Passage of the language prohibiting use of federal funds in going after states that have legalized medical marijuana underscores growing bipartisan political support for marijuana legalization. If that support continues to grow, it could lead to changes to federal marijuana laws.
These changes would help marijuana growers and retailers but could also positively affect biotechs focusing on cannabinoid development. Marijuana-legalization supporters hope to enact legislation that makes it easier for companies such as Axim Biotechnologies to conduct clinical studies using cannabis in the United States.It's possible that the temporary budget bill could be one step along the path that ultimately leads totruly good news for marijuana stocks down the road.
10 stocks we like better than AXIM BIOTECHNOLOGIESWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AXIM BIOTECHNOLOGIES wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017